Loading organizations...
Loading organizations...

Convexia: AI platform automating pharmaceutical drug discovery and development for pharma and biotech, focused on drug asset evaluation.
Key people at Convexia.
Convexia was founded in 2025 by Rahul Vijayan ( Co-Founder & CTO) and Ayaan Parikh (Founder).
San Francisco-based Convexia operates an artificial intelligence platform that automates the pharmaceutical drug discovery and development process through global asset sourcing, scientific evaluation, commercial analysis, and clinical risk assessment. The business-to-business software platform utilizes 50 custom-tuned AI models to evaluate specific drug properties such as binding, toxicity, and immunogenicity, replacing months of manual analysis with automated workflows. The company currently provides its technology to pharmaceutical business development teams, biotechnology startups, and rare disease clinician teams, with long-term plans to eventually acquire and advance its own drug assets. Operating with a team of four employees, the enterprise is backed by startup accelerator Y Combinator and works alongside primary partner Ankit Gupta to identify overlooked or abandoned therapeutics globally before specialist human review. Convexia was founded in 2025 by Stanford University alumnus Ayaan Parikh and Rahul Vijayan.
Convexia is the world's first AI-maximalist pharmaceutical company that leverages autonomous AI agents to revolutionize drug sourcing, evaluation, clinical trials, and commercialization. Its platform operates 10x faster and 20x leaner than traditional pharma by automating the entire drug diligence and development lifecycle. Convexia buys overlooked or abandoned drug assets, runs clinical trials, and sells the drugs for profit, targeting inefficiencies in the trillion-dollar pharmaceutical industry where manual diligence slows innovation[1][2][3][5].
The company serves pharmaceutical companies, biotech investors, and computational biotechs by accelerating drug asset discovery and evaluation. Its AI-driven approach addresses the problem of life-saving drugs being shelved or overlooked due to slow, costly, and outdated manual processes. Convexia is currently running pilots with early customers to demonstrate value and build traction, showing promising growth momentum as it licenses components of its AI platform and prepares to operate the full drug lifecycle independently[1][2][3].
Convexia was founded in 2025 by Ayaan Parikh and Rahul Vijayan, Stanford computer science dropouts who have previously co-founded and exited three startups together. The idea emerged from their recognition that the pharmaceutical industry is heavily bloated and antiquated, with drug diligence still largely manual and inefficient. They envisioned an AI-driven platform that could autonomously scout, vet, and accelerate drug assets globally, transforming how drugs are sourced and developed[1][3][5].
The founders met in 8th grade and have been building startups together since high school. Their combined entrepreneurial experience and technical expertise shaped Convexia’s AI-maximalist approach. Early traction includes backing from Y Combinator (Summer 2025 batch) and active pilot programs with pharma and biotech partners, positioning Convexia as a potential unicorn in the AI-powered pharma space[3][4][5].
Convexia rides the wave of AI-driven transformation in biotech and pharma, addressing a critical bottleneck in drug development: slow, manual diligence and asset evaluation. The timing is crucial as AI capabilities in computational biology, data integration, and simulation mature, enabling real-world applications beyond theoretical models[2][3].
Market forces favor Convexia’s approach due to the pharmaceutical industry’s urgent need to reduce costs and accelerate innovation amid rising R&D expenses and patent cliffs. By automating drug sourcing and evaluation, Convexia can unlock overlooked assets globally, democratizing access to promising therapies and reshaping how drugs enter the market[1][3].
Convexia’s influence extends to the startup ecosystem by offering a new model for AI-powered drug development, encouraging collaboration between AI innovators, pharma operators, and biotech investors. Its pilot partnerships and licensing strategy foster a community that bridges AI and life sciences, potentially accelerating the pace of drug discovery and commercialization industry-wide[1][2].
Convexia is positioned to become a disruptive force in pharmaceutical R&D by fully automating the drug lifecycle with AI. The next steps involve scaling its platform from pilot licensing to direct acquisition, clinical trial management, and drug sales, aiming to prove the economic and operational superiority of its AI-maximalist model.
Future trends shaping Convexia’s journey include advances in AI interpretability, integration of multi-omics data, and regulatory acceptance of AI-driven drug development. As AI becomes more embedded in pharma workflows, Convexia’s influence may expand from a niche innovator to a mainstream player, potentially setting new industry standards for speed, cost-efficiency, and drug asset utilization.
By addressing the pharmaceutical industry's entrenched inefficiencies with cutting-edge AI, Convexia exemplifies how technology can unlock hidden value and accelerate life-saving therapies, fulfilling its mission to transform drug development for the better[1][2][3][5].
Convexia was founded in 2025 by Rahul Vijayan ( Co-Founder & CTO) and Ayaan Parikh (Founder).
Key people at Convexia.